Pharmaxis
is an Australia-based pharmaceutical company that develops and markets mechanism-based therapies to treat inflammatory and fibrotic diseases... Read morePharmaxis
is an Australia-based pharmaceutical company that develops and markets mechanism-based therapies to treat inflammatory and fibrotic diseases... Read more
News
Dec 13, 2023
Proactive Investors
Pharmaxis: Syntara doses first patient in bone cancer Phase 2 trial assessing SNT-5505 in combination with ruxolitinib
Dec 08, 2023
Trinitydigest
Pharmaxis: Myelofibrosis Pipeline Drugs Analysis Report (2023 Updates): FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | Pharmaxis, MorphoSys, Merck, AbbVie, Suzhou Zelgen Biopharma, Geron
Oct 18, 2023
Proactive Investors
Pharmaxis: Pharmaxis finalises sale of MBU to Arna Pharma; shifts focus to blood-related cancer treatments
Oct 05, 2023
LabOnline
Pharmaxis: Pancreatic cancer drug targets scar-like tumour tissue
Oct 04, 2023
Pharamceutical Technology
Pharmaxis: PXS-5505A by Pharmaxis for Pancreatic Ductal Adenocarcinoma: Likelihood of Approval
Aug 30, 2023
Proactive Investors
Pharmaxis: Pharmaxis increases survival rate by 35% in pre-clinical models of pancreatic cancer with drug discovery PXS5505
Aug 28, 2023
Marketscreener
Pharmaxis: Pharmaxis Ltd Reports Earnings Results for the Full Year Ended June 30, 2023
Jul 12, 2023
The Market Herald
Pharmaxis: Pharmaxis (ASX:PXS) releases "excellent" final set of interim data from phase two cancer trial
May 25, 2023
Yahoo
Pharmaxis: Pharmaxis extends scarring collaboration after encouraging results
Apr 12, 2023
Stockhead
Pharmaxis: ASX Health Stocks: Pharmaxis and Aroa lift on FDA news, Cynata to commence Phase 2 trial
Pharmaxis Competitors
1
2
3
4
5
6